Cardisan 2.5 mg chewable tablets for dogs

Authorised

- Pimobendan

Product identification

Medicine name:
Cardisan 2.5 mg chewable tablets for dogs

Active substance:
Pimobendan

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Pimobendan
2.50 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Chewable tablet

Withdrawal period by route of administration:

Oral use:

- **Dog**
  - All relevant tissues. no withdrawal period — Not applicable

---

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QC01CE90

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:

Valid

Authorised in:

Germany

Package description:

Cardbox containing 12 Aluminium-OPA/Aluminium/PVC blisters containing 10 tablets each.
Cardbox containing 10 Aluminium-OPA/Aluminium/PVC blisters containing 10 tablets each.
Cardbox containing 9 Aluminium-OPA/Aluminium/PVC blisters containing 10 tablets each.
Cardbox containing 6 Aluminium-OPA/Aluminium/PVC blisters containing 10 tablets each.
Cardbox containing 3 Aluminium-OPA/Aluminium/PVC blisters containing 10 tablets each.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
Alfasan Nederland B.V.

Marketing authorisation date:
22/11/2022

Manufacturing sites for batch release:
Alfasan Nederland B.V.
Lelypharma B.V.

Responsible authority:
Federal Office Of Consumer Protection And Food Safety

Authorisation number:
V7007464.00.00

Date of authorisation status change:
22/11/2022

Reference member state:
Netherlands

Procedure number:
NL/V/0380/002

Concerned member states:
Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland France Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania Luxembourg Malta Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 28/12/2022
Download